Median Technologies Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials
31 Mai 2022 - 5:45PM
Business Wire
- With Imaging Lab, Median will provide biopharmaceutical
companies with new decision-making tools for clinical trials by
leveraging images with data mining and Artificial Intelligence (AI)
technologies from iBiopsy® and radiomics
- Imaging Lab's solutions will support the pharmaceutical
industry's paradigm shift towards therapies targeting patients with
early-stage cancers
- The Imaging Lab team will be exhibiting at the ASCO Annual
Conference in Chicago, June 3-7, 2022, Median’s booth #2098,
Exhibit Hall A, McCormick place
Regulatory News:
Median Technologies (Paris:ALMDT) announces that the company is
expanding its portfolio of services with Imaging Lab, a new entity
whose mission is to leverage AI, data mining, and radiomics
technologies to exploit imaging data from clinical trials in
oncology.
The creation of Imaging Lab materializes the convergence of
iCRO's activities for image management in the development of new
oncologic drugs and iBiopsy®'s activities for the development of
software as medical device targeting early diagnosis of cancers,
especially lung cancer.
"We are seeing a paradigm shift of pharmaceutical companies
towards new drug candidates targeting patients with early-stage
cancers," said Fredrik Brag, CEO and founder of Median
Technologies. "The synergy between our iCRO and iBiopsy® businesses
is perfect to respond to this change: iBiopsy® develops software as
medical device, integrating AI technologies, which allow the
diagnosis of diseases at a very early stage, when patients are
still asymptomatic. At the same time, iCRO has extensive knowledge
of image processing and its management in clinical trials. The
cross-fertilization of our two businesses will enable us to
leverage imaging data in conjunction with other clinical
information in an unparalleled way and provide biopharmaceutical
companies with tools for Go/No-Go decisions in trials," adds
Fredrik Brag.
Imaging Lab will provide new answers in four areas that
determine the success of clinical trials: selection of patients
included in trials, especially inclusion of patients diagnosed at
early stages of disease thanks to AI technologies, prediction of
response to therapy, measurement of disease progression, and
evaluation of the safety of drug candidates. The goal is to
optimize development plans, including facilitating Go/No-Go
decisions to increase the success rate of clinical trials. This
rate is especially low in oncology, generating an average
development cost of $2.8 billion to take a new molecule to market,
compared with an average of $1 billion per new molecule brought to
market for other therapeutic areas1.
"Our experience of image management in clinical trials has shown
that trial data is vastly underutilized. We can extract much more
information from images through the widescale use of data mining,
AI, and radiomics and use these technologies to better support our
customers and biopharmaceutical partners in their clinical
developments," says Nicolas Dano, COO iCRO of Median
Technologies.
The Imaging Lab team will be present from June 4-6 (exhibition
dates) at the ASCO Annual Conference in Chicago , Median’s booth
#2098, Exhibit Hall A, to meet the pharmaceutical community.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and iBiopsy®, our
AI-powered software as medical device help biopharmaceutical
companies and clinicians to bring new treatments and diagnose
patients earlier and more accurately. This is how we are helping to
create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME), is part of the Enternext® PEA-PME 150 index and has been
awarded the Euronext European Rising Tech label. For more
information: www.mediantechnologies.com
1
https://www.biopharmadive.com/news/new-drug-cost-research-development-market-jama-study/573381/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220531005703/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Median Technologies (EU:ALMDT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024